Bli medlem
Bli medlem

Du är här

2017-03-22

Karolinska Development AB (publ): Karolinska Development company Aprea Therapeutics Announces Research Collaboration with Memorial Sloan Kettering Cancer Center

STOCKHOLM - March 22, 2017. Karolinska Development's portfolio company
Aprea Therapeutics, a privately held, clinical stage biopharmaceutical company
developing novel anticancer therapies targeting the tumor suppressor protein
p53, today announced a collaboration with Memorial Sloan Kettering Cancer
Center to study the effects of reactivation of tumor suppressor protein p53
by APR-246
.

Details from the Aprea Therapeutics press release follow:

The goal of the collaboration is to evaluate and characterize preclinical
efficacy of APR-246 in combination with multiple other anti-cancer agents and
across multiple tumor types. The Principal Investigator of the study is Taha
Merghoub, Ph.D., and he will be conducting the research in collaboration with
the laboratory of Jedd D. Wolchok, M.D., Ph.D., Chief of Melanoma and
Immunotherapeutics Service, Department of Medicine.

"We are excited to initiate this new collaboration with Memorial Sloan
Kettering," said Christian S. Schade, President and Chief Executive Officer
of Aprea Therapeutics AB. "These studies will not only provide important
insight into the effects of APR-246-induced p53 reactivation but also inform
the rationale for novel combination therapies to be tested in future clinical
trials."

For further information, please contact:

Jim Van heusden, CEO, Karolinska Development AB

Phone: +46 72 858 32 09, e-mail:jim.van.heusden@karolinskadevelopment.com

Viktor Drvota, Deputy CEO and Chief Investment Officer, Karolinska Development
AB

Phone: +46 73 982 52 02, e-mail:viktor.drvota@karolinskadevelopment.com

David Dible/Mark Swallow/Pip Batty, Citigate Dewe Rogerson

Phone: +44 20 7638 9571; e-mail:KDev@citigatedr.co.uk

TO THE EDITORS

About Aprea Therapeutics AB

Aprea Therapeutics AB is a Boston, Massachusetts- and Stockholm, Sweden-based
biopharmaceutical company focused on the discovery and development of novel
anticancer compounds reactivating the tumor suppressor protein, p53. The
Company's lead program, APR-246, a first-in-class small molecule drug
candidate, is in Phase II clinical development in ovarian cancer patients,
and additional clinical studies with APR-246 in other cancer indications are
planned. In March 2016, Aprea completed a EUR 46 million Series B financing
with an international syndicate co-led by Versant Ventures and 5AM Ventures,
with additional participation by Sectoral Asset Management, HealthCap, acting
as local lead investor, and existing investor, Karolinska Development. For
more information, please visitwww.apreatherapeutics.com.

About p53 and APR-246

The p53 tumor suppressor gene is the most frequently mutated gene in human
cancer, occurring in approximately 50% of all human tumors. These mutations
are often associated with resistance to anticancer drugs and poor overall
survival, representing a major unmet medical need in the treatment of cancer.

APR-246 has been shown to reactivate mutant p53 protein - by reconverting
mutant p53 into wild-type p53 conformation and function - and thereby induce
programmed cell death in human cancer cells. APR- 246 has demonstrated
compelling pre-clinical antitumor activity in a wide variety of solid and
hematological (blood) tumors, including ovarian cancer, small cell lung
cancer, esophageal cancer and AML (acute myeloid leukemia), among others.
Additionally, strong synergy has been seen with both traditional anticancer
agents, such as chemotherapy, as well as newer mechanism-based anticancer
drugs and immuno-oncology checkpoint inhibitors. In addition to pre-clinical
testing, Phase I clinical studies with APR-246 have been completed,
demonstrating a favorable safety profile and both biological and clinical
responses in hematological malignancies and solid tumors with mutations in
the p53 gene. The Company has commenced a Phase II study on ovarian cancer
and is expecting to initiate additional clinical studies of APR-246 in other
cancer indications.

About Karolinska Development AB

Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences
investment company. The company focuses on identifying breakthrough medical
innovations in the Nordic region that are developed by entrepreneurs and
leadership teams. The Company invests in the creation and growth of companies
that advance these assets into commercial products that are designed to make
a difference to patients' lives while providing an attractive return on
investment to shareholders.

Karolinska Development has access to world-class medical innovations at the
Karolinska Institutet and other leading universities and research institutes
in the Nordic region. The Company aims to build companies around scientists
who are leaders in their fields, supported by experienced management teams
and advisers, and co-funded by specialist international investors, to provide
the greatest chance of success.

Karolinska Development has established a portfolio of nine companies targeting
opportunities in innovative treatment for life-threatening or serious
debilitating diseases.

The Company is led by an entrepreneurial team of investment professionals with
a proven track record as company builders and with access to a strong global
network.

For more information, please visitwww.karolinskadevelopment.com

KD Aprea MSK (ENG)
http://hugin.info/143071/R/2089692/788955.pdf

---------------------------------------
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Karolinska Development AB (publ) via Globenewswire

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.